Study Summary
This study aims to evaluate the safety and efficacy of LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells) in patients with refractory or relapsed acute myeloid leukemia(AML).
Want to learn more about this trial?
Request More InfoInterventions
Anti-LILRA6 CAR-T cellsBIOLOGICAL
lentiviral vector-transducted peripheral blood-derived T cells to express anti-LILRA6 CAR
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The Second Affiliated Hospital,School of Medicine,Zhejiang University | Hangzhou | Zhejiang | China |